Announcement

Collapse
No announcement yet.

Siponimod Reduces Disease Activity Biomarker in SPMS Patients

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

    Siponimod Reduces Disease Activity Biomarker in SPMS Patients

    Novartis‘ siponimod (BAF312) can reduce blood levels of a biomarker of nerve cell damage in patients with secondary progressive multiple sclerosis (SPMS), a Phase 3 clinical trial shows.

    Researchers will present the latest results of the ongoing trial at the 2018 annual meeting of the American Academy of Neurology in Los Angeles, April 21-27. The presentation will be titled “Siponimod Reduces Neurofilament Light Chain Blood Levels in Secondary Progressive Multiple Sclerosis Patients.”

    Read more- https://multiplesclerosisnewstoday.c...e6abe-72871989

    Can we be hopeful that siponimod can reduce SPMS activity??
    1st sx '89 Dx '99 w/RRMS - SP since 2010
    Administrator Message Boards/Moderator
Working...
X